A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies

Background: Receptor tyrosine kinases (RTKs) play key roles in tumorigenesis. The multi-RTK inhibitor dovitinib has demonstrated promising antitumor activity in multiple cancers. Patients and Methods: In this phase 2, open-label, single-arm study, patients with advanced malignancies with RTK-pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Matthew H., Alva, Ajjai S., Larson, Timothy, Szpakowski, Sebastian, Purkaystha, Das, Amin, Alpesh, Karpiak, Linda, Piha-Paul, Sarina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147086/
https://www.ncbi.nlm.nih.gov/pubmed/32292573
http://dx.doi.org/10.18632/oncotarget.27530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147086/
https://www.ncbi.nlm.nih.gov/pubmed/32292573
http://dx.doi.org/10.18632/oncotarget.27530

Ejemplares similares